Swiss Group for Clinical Cancer Research
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
Gautschi O, Savic S, Jaggi R, Leibundgut E, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein A, Bubendorf L, Feilchenfeldt J, Rauch D, Mach N, Rothschild S, Li Q, Stahel R, Zippelius A, Cathomas R, Früh M, Betticher D, Peters S, Swiss Group for Clinical Cancer Research. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. Clin Lung Cancer 2015; 16:358-65.
05.03.2015Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
05.03.2015Clin Lung Cancer 2015; 16:358-65
Gautschi Oliver, Savic Spasenija, Jaggi Rolf, Leibundgut Elisabeth Oppliger, Largiadèr Carlo, Brutsche Martin, Pilop Christiane, Stalder Lukas, Pless Miklos, Ochsenbein Adrian F, Bubendorf Lukas, Feilchenfeldt Jonas, Rauch Daniel, Mach Nicholas, Rothschild Sacha I, Li Qiyu, Stahel Rolf A, Zippelius Alfred, Cathomas Richard, Früh Martin, Betticher Daniel C, Peters Solange, Swiss Group for Clinical Cancer Research
EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
Baty F, Brutsche M, Pless M, Zappa F, Crowe S, Bubendorf L, Gautschi O, Rauch D, Cathomas R, Dröge C, Betticher D, Früh M, Rothschild S, Swiss Group for Clinical Cancer Research. EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer. PloS one 2013; 8:e72966.
10.09.2013EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
10.09.2013PloS one 2013; 8:e72966
Baty Florent, Brutsche Martin, Pless Miklos, Zappa Francesco, Crowe Susanne, Bubendorf Lukas, Gautschi Oliver, Rauch Daniel, Cathomas Richard, Dröge Cornelia, Betticher Daniel, Früh Martin, Rothschild Sacha, Swiss Group for Clinical Cancer Research
Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08)
Früh M, Pless M, Fustier P, Küttel E, Simcock M, Rauch D, Krasniqi F, Erdmann A, Mamot C, Zippelius A, Tscherry G, Siano M, Cathomas R, Swiss Group for Clinical Cancer Research. Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08). Clin Lung Cancer 2012; 14:34-9.
24.05.2012Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08)
24.05.2012Clin Lung Cancer 2012; 14:34-9
Früh Martin, Pless Miklos, Fustier Pierre, Küttel Erika, Simcock Mathew, Rauch Daniel, Krasniqi Fatima, Erdmann Andreas, Mamot Christoph, Zippelius Alfred, Tscherry Gregor, Siano Marco, Cathomas Richard, Swiss Group for Clinical Cancer Research
Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research
Koeberle D, Herrmann R, Mora O, Ruhstaller T, Strasser F, Beretta K, Mingrone W, Caspar C, Dietrich D, Gerber D, Borner M, Saletti P, Swiss Group for Clinical Cancer Research. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008; 26:3702-8.
01.08.2008Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research
01.08.2008Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008; 26:3702-8
Koeberle Dieter, Herrmann Richard, Mora Oreste, Ruhstaller Thomas, Strasser Florian, Beretta Kurt, Mingrone Walter, Caspar Clemens B, Dietrich Daniel, Gerber Daniela, Borner Markus, Saletti Piercarlo, Swiss Group for Clinical Cancer Research
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research
Roth A, de Braud F, Seymour M, Widmer L, Glynne-Jones R, Leslie M, Wernli M, Maibach R, Rufibach K, Borner M, Köberle D, Saletti P, Bernhard J, Falk S, Stupp R, Fazio N, Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007; 25:3217-23.
01.08.2007Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research
01.08.2007Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007; 25:3217-23
Roth Arnaud D, de Braud Filippo, Seymour Matthew, Widmer Lukas, Glynne-Jones Robert, Leslie Martin, Wernli Martin, Maibach Rudolf, Rufibach Kaspar, Borner Markus M, Köberle Dieter, Saletti Piercarlo, Bernhard Jürg, Falk Stephen, Stupp Roger, Fazio Nicola, Swiss Group for Clinical Cancer Research
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
Herrmann R, Stemmer S, Tàmas K, Kornek G, Köberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W, Swiss Group for Clinical Cancer Research, Mingrone W, Köhne C, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Central European Cooperative Oncology Group. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007; 25:2212-7.
01.06.2007Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
01.06.2007Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007; 25:2212-7
Herrmann Richard, Stemmer Salomon M, Tàmas Karin, Kornek Gabriela V, Köberle Dieter, Cina Susanne, Bernhard Jürg, Dietrich Daniel, Scheithauer Werner, Swiss Group for Clinical Cancer Research, Mingrone Walter, Köhne Claus-Henning, Bodoky György, Ruhstaller Thomas, Glimelius Bengt, Bajetta Emilio, Schüller Johannes, Saletti Piercarlo, Bauer Jean, Figer Arie, Pestalozzi Bernhard, Central European Cooperative Oncology Group
Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99)
Hess D, Ribi K, Ballabeni P, Schuller J, Rauch D, Rochlitz C, Mattmann S, Schonenberger A, Pagani O, Thürlimann B, Köberle D, Swiss Group for Clinical Cancer Research. Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). Oncology 2007; 73:228-37.
01.01.2007Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99)
01.01.2007Oncology 2007; 73:228-37
Hess Dagmar, Ribi K, Ballabeni P, Schuller J C, Rauch D, Rochlitz C, Mattmann S, Schonenberger A, Pagani O, Thürlimann Beat, Köberle Dieter, Swiss Group for Clinical Cancer Research
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas
Leyvraz S, Honegger H, Dietrich D, Fey M, Sessa C, Cerny T, Lissoni A, Jundt G, Zweifel M, Swiss Group for Clinical Cancer Research. Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006; 17:646-51.
01.04.2006Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas
01.04.2006Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006; 17:646-51
Leyvraz S, Honegger H P, Dietrich D, Fey M, Sessa C, Cerny Thomas, Lissoni A, Jundt G, Zweifel M, Swiss Group for Clinical Cancer Research
Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)
Ghielmini M, Cerny T, Bargetzi M, Ketterer N, Stahel R, Pichert G, Schefer H, Betticher D, Fey M, Waltzer U, Bertoni F, Cogliatti S, Schmitz S, Swiss Group for Clinical Cancer Research. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005; 23:705-11.
01.02.2005Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)
01.02.2005Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005; 23:705-11
Ghielmini Michele, Cerny Thomas, Bargetzi Mario, Ketterer Nicolas, Stahel Rolf, Pichert Gabriella, Schefer Hubert, Betticher Daniel C, Fey Martin F, Waltzer Ursula, Bertoni Francesco, Cogliatti Sergio, Schmitz Shu-Fang Hsu, Swiss Group for Clinical Cancer Research
Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research
Bertoni F, Cotter F, Cavalli F, Zucca E, Auer R, Jones C, Baldini L, Ponzoni M, Bertolini F, Pichert G, Fey M, Cerny T, Ghielmini M, Schmitz S, Cogliatti S, Conconi A, Swiss Group for Clinical Cancer Research. Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research. British journal of haematology 2004; 124:289-98.
01.02.2004Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research
01.02.2004British journal of haematology 2004; 124:289-98
Bertoni Francesco, Cotter Finbarr E, Cavalli Franco, Zucca Emanuele, Auer Rebecca, Jones Chris, Baldini Luca, Ponzoni Maurilio, Bertolini Francesco, Pichert Gabriella, Fey Martin, Cerny Thomas, Ghielmini Michele, Schmitz Shu-Fang Hsu, Cogliatti Sergio B, Conconi Annarita, Swiss Group for Clinical Cancer Research
A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis
Aapro M, Thürlimann B, Sessa C, De Pree C, Bernhard J, Maibach R, Swiss Group for Clinical Cancer Research. A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003; 14:291-7.
01.02.2003A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis
01.02.2003Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003; 14:291-7
Aapro M S, Thürlimann Beat, Sessa C, De Pree C, Bernhard J, Maibach R, Swiss Group for Clinical Cancer Research
Patients' estimation of overall treatment burden: why not ask the obvious?
Bernhard J, Maibach R, Thürlimann B, Sessa C, Aapro M, Swiss Group for Clinical Cancer Research. Patients' estimation of overall treatment burden: why not ask the obvious?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002; 20:65-72.
01.01.2002Patients' estimation of overall treatment burden: why not ask the obvious?
01.01.2002Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002; 20:65-72
Bernhard J, Maibach R, Thürlimann Beat, Sessa C, Aapro M S, Swiss Group for Clinical Cancer Research